According to published data, CD19 targeted therapy of B-ALL with blinatumomab or αCD19 CAR-T cells may lead to myeloid switch (28–30), and B-cell precursor ALL is prone to myeloid switch under standard intensive ALL-like treatment (31, 32). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.